EUVIMEDEUVIMED entdecken
Crossref

QbD-Guided Development, Optimization, and In-Vitro Characterization of a Dual-Release Bilayer Tablet System of Metoprolol Succinate Extended Release and Chlorthalidone Immediate Release for Improved Hypertension Therapy

P.V. Burakle, Poonam S. Yelhekar

International Journal of Drug Delivery Technology · 06.07.2026 · 16 (62s)

DOI: 10.25258/ijddt.16.62s.170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 06.07.2026. Verfasst von P.V. Burakle und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension remains one of the most prevalent cardiovascular disorders worldwide and is a major risk factor for stroke, myocardial infarction, heart failure, and chronic kidney disease. Combination therapy employing antihypertensive agents with complementary mechanisms of action has demonstrated superior blood pressure control compared with monotherapy. The present study aimed to develop and optimize a dual-release bilayer tablet comprising Metoprolol Succinate as an extended-release (ER) layer and Chlorthalidone as an immediate-release (IR) layer using the Quality by Design (QbD) approach. The immediate-release layer was formulated using superdisintegrants to achieve rapid drug release, while the extended-release layer employed hydrophilic polymers to provide sustained drug delivery over 24 hours. A Design of Experiments based optimization strategy was applied to establish the design space and optimize formulation variables. The developed bilayer tablets were evaluated for physicochemical properties, drug content uniformity, hardness, friability, disintegration time, dissolution behavior, and drug release kinetics. The optimized formulation demonstrated satisfactory tablet characteristics, rapid release of Chlorthalidone within the initial period, and controlled release of Metoprolol Succinate extending up to 24 hours. Drug release profiles were comparable to marketed formulations and complied with Pharmacopoeial specifications. The study confirmed that the QbD-based bilayer tablet system provides a robust platform for sequential drug delivery and may improve patient compliance, therapeutic efficacy, and hypertension management.

Zitieren

APA

Burakle, P., & Yelhekar, P. S. (2026). QbD-Guided Development, Optimization, and In-Vitro Characterization of a Dual-Release Bilayer Tablet System of Metoprolol Succinate Extended Release and Chlorthalidone Immediate Release for Improved Hypertension Therapy. International Journal of Drug Delivery Technology, 16(62s). https://doi.org/10.25258/ijddt.16.62s.170

Vancouver

Burakle P, Yelhekar PS. QbD-Guided Development, Optimization, and In-Vitro Characterization of a Dual-Release Bilayer Tablet System of Metoprolol Succinate Extended Release and Chlorthalidone Immediate Release for Improved Hypertension Therapy. International Journal of Drug Delivery Technology. 2026;16(62s). doi:10.25258/ijddt.16.62s.170

BibTeX
@article{Burakle2026,
  author = {Burakle, P.V. and Yelhekar, Poonam S.},
  title = {QbD-Guided Development, Optimization, and In-Vitro Characterization of a Dual-Release Bilayer Tablet System of Metoprolol Succinate Extended Release and Chlorthalidone Immediate Release for Improved Hypertension Therapy},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {62s},
  doi = {10.25258/ijddt.16.62s.170}
}
Kostenlos starten →